Atze van der Pol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7746916/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treating oxidative stress in heart failure: past, present and future. European Journal of Heart Failure, 2019, 21, 425-435.	7.1	407
2	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 457-462.	3.9	60
3	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882.	3.8	38
4	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	12.4	36
5	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS ONE, 2017, 12, e0177242.	2.5	25
6	<i>In Vitro</i> Methods to Model Cardiac Mechanobiology in Health and Disease. Tissue Engineering - Part C: Methods, 2021, 27, 139-151.	2.1	21
7	Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart. Journal of Internal Medicine, 2020, 288, 491-506.	6.0	20
8	LC-MS analysis of key components of the glutathione cycle in tissues and body fluids from mice with myocardial infarction. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 289-296.	2.8	15
9	Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?. European Journal of Heart Failure, 2012, 14, 1-4.	7.1	4
10	A Brief History in Cardiac Regeneration, and How the Extra Cellular Matrix May Turn the Tide. Frontiers in Cardiovascular Medicine, 2021, 8, 682342.	2.4	2
11	Abstract 19908: 5-oxoprolinase: a Novel Cardiac Mediator of the Oxidative Stress Response in the Failing Heart, Circulation, 2014, 130	1.6	0